The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer
- PMID: 28993275
- DOI: 10.1016/j.humpath.2017.09.012
The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer
Abstract
Compelling evidence has demonstrated the prognostic value of tumor-infiltrating lymphocytes (TILs), especially in triple-negative breast cancer (TNBC). However, only a limited number of studies to investigate the importance of the subsets of T cells in TILs have been carried out, less so the significance of the location of these TILs. In this study, we explored in a cohort of 42 consecutive TNBC cases the prognostic significance of TIL subsets at the tumor-host interface (within 1 high-power field [0.5 mm] of the invasive front) and compared them with TILs within the intratumoral stroma. Given the reported importance of TILs in HER2-overexpressing breast cancer, a subset of such tumors was also included for comparison. The range was wide in both locations; nevertheless, the mean CD4+ and CD8+ T cell count was significantly higher at the tumor-host interface than that found within the intratumoral stroma (both P<.0001). The number of CD4+ or CD8+ T cells at either location was not significantly associated with distant relapse-free or overall survival. However, the CD4/CD8 ratio at the tumor-host interface was significantly associated with both relapse-free survival (hazard ratio 0.2, P=.002) and overall survival (hazard ratio 0.13, P=.002), whereas this association was not seen for the CD4/CD8 ratio within the intratumoral stroma. As expected, both tumor size and nodal status were significantly associated with survival outcomes. The findings further support the contention that TILs, as markers of regional immune escape, are of prognostic importance in TNBC progression and that the CD4/CD8 ratio of TILs at the tumor-host interface plays a distinctive role, thus appearing to be of clinical relevance.
Keywords: Breast cancer; CD4; CD8; Triple negative; Tumor-infiltrating lymphocytes.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
-
Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.Breast Cancer Res Treat. 2016 Apr;156(2):237-47. doi: 10.1007/s10549-016-3743-x. Epub 2016 Mar 9. Breast Cancer Res Treat. 2016. PMID: 26960711
-
Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.Chemotherapy. 2017;62(4):246-255. doi: 10.1159/000470900. Epub 2017 May 5. Chemotherapy. 2017. PMID: 28472798
-
Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.BMC Cancer. 2021 Mar 16;21(1):286. doi: 10.1186/s12885-021-08009-x. BMC Cancer. 2021. PMID: 33726701 Free PMC article.
-
The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.Breast Cancer Res Treat. 2014 Dec;148(3):467-76. doi: 10.1007/s10549-014-3185-2. Epub 2014 Nov 1. Breast Cancer Res Treat. 2014. PMID: 25361613 Review.
-
Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.BMC Cancer. 2020 Mar 4;20(1):179. doi: 10.1186/s12885-020-6668-z. BMC Cancer. 2020. PMID: 32131780 Free PMC article.
Cited by
-
Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma.Front Immunol. 2020 Sep 10;11:2105. doi: 10.3389/fimmu.2020.02105. eCollection 2020. Front Immunol. 2020. PMID: 33013886 Free PMC article. Review.
-
Piezo1 facilitates optimal T cell activation during tumor challenge.Oncoimmunology. 2023 Nov 22;12(1):2281179. doi: 10.1080/2162402X.2023.2281179. eCollection 2023. Oncoimmunology. 2023. PMID: 38126029 Free PMC article.
-
Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications.Front Immunol. 2024 Dec 6;15:1497522. doi: 10.3389/fimmu.2024.1497522. eCollection 2024. Front Immunol. 2024. PMID: 39712007 Free PMC article. Review.
-
Immune parameters associated with survival in metaplastic breast cancer.Breast Cancer Res. 2020 Aug 18;22(1):92. doi: 10.1186/s13058-020-01330-6. Breast Cancer Res. 2020. PMID: 32811533 Free PMC article.
-
Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes.Cancers (Basel). 2022 Apr 12;14(8):1942. doi: 10.3390/cancers14081942. Cancers (Basel). 2022. PMID: 35454849 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous